Patents by Inventor Igor Splawski

Igor Splawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • mRNA-mediated immunization methods
    Patent number: 11878060
    Abstract: The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 23, 2024
    Assignee: Novartis AG
    Inventors: John Dominy, Robert Dunn, Scott Glaser, Mark Keating, Carla Klattenhoff, Igor Splawski
  • ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
    Publication number: 20220213181
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Inventors: Regis CEBE, Igor SPLAWSKI, John TRAUGER, Andrei Igorevich VOZNESENSKY
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20210355206
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Joy Gispati GHOSH, Michael ROGUSKA, Mark Anthony RUTZ, Igor SPLAWSKI, Kathrin Ulrike TISSOT-DAGUETTE
  • MRNA-MEDIATED IMMUNIZATION METHODS
    Publication number: 20210283262
    Abstract: The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).
    Type: Application
    Filed: August 4, 2017
    Publication date: September 16, 2021
    Inventors: John DOMINY, Robert DUNN, Scott GLASER, Mark KEATING, Carla KLATTENHOFF, Igor SPLAWSKI
  • Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • Nucleic acids encoding anti-Factor P antibodies
    Patent number: 10865237
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 15, 2020
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20200048341
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: July 3, 2019
    Publication date: February 13, 2020
    Inventors: Joy GHOSH, Michael ROGUSKA, Mark Anthony RUTZ, Igor SPLAWSKI, Kathrin Ulrike TISSOT-DAGUETTE
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 10407496
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: September 10, 2019
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • Compositions and methods for antibodies targeting EPO
    Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20190135913
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: September 13, 2018
    Publication date: May 9, 2019
    Applicant: NOVARTIS AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Kathrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190040128
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 7, 2019
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20180327486
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: May 7, 2018
    Publication date: November 15, 2018
    Applicant: Novartis AG
    Inventors: Leslie Ngozi Anuna JOHNSON, Ute JAEGER, Yong-In KIM, Christian Carsten Silvester KUNZ, Igor SPLAWSKI, Michael ROGUSKA, Joy GHOSH, Barbara BRANNETTI, Michael STEFANIDAKIS, Sha-Mei LIAO
  • Compositions and methods for antibodies targeting Epo
    Patent number: 10106605
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 23, 2018
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Compositions comprising antibodies targeting factor P
    Patent number: 9988440
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20170260260
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 14, 2017
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170152313
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
    Publication number: 20160367638
    Abstract: A formulation comprising a modified synthetic messenger RNA and a delivery agent. The modified synthetic messenger RNA encodes a leptin protein, is non-replicating and is translation-ready. The formulation can be delivered to a subject with congenital leptin deficiency, lipodystrophy or other condition where circulating leptin level is low.
    Type: Application
    Filed: December 17, 2014
    Publication date: December 22, 2016
    Inventors: Crystal BYERS, Shari Lynn CAPLAN, Gabriel Grant GAMBER, Seung HAHM, Kurt Alex HELDWEIN, Igor SPLAWSKI, Thomas ZABAWA, Frédéric ZECRI
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20160280783
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: June 13, 2016
    Publication date: September 29, 2016
    Applicant: Novartis AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Kathrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA